Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issue
1-2
Table of Contents
Editors Selection
Glaucoma Dialogue
Glaucoma Opinion
Abstracts
Abstracts
Abstracted Journals
Classification List
Index of Authors
Search
Home
Abstracts
Classification
Classification #11.4
advertisement
11.4 Prostaglandins
(20)
Showing records 1 to 20
Display all abstracts in classification
11.4 Prostaglandins
Search within classification 11.4 Prostaglandins
5241
Superior cervical ganglionectomy-induced lowering of intraocular pressure in rabbits: role of prostaglandins and neuropeptide Y.
Zhan GL; Ohia SE; Camras CB; Ohia EO; Wang YL
General Pharmacology
1999; 32: 189-194
5358
The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients
Konstas AGP; Maltezos A; Mantziris DA; Sine CS; Stewart WC
Eye
1999; 13: 314-318
5398
Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension
Kent AR; Vroman DT; Thomas TJ; Hebert RL; Crosson CE
Journal of Glaucoma
1999; 8: 257-262
5403
Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents (see comments)
Maus TL; Nau C; Brubaker RF
Archives of Ophthalmology
1999; 117: 586-591
5410
Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open- angle glaucoma
Konstas AGP; Maltezos AC; Gandi S; Hudgins AC; Stewart WC
American Journal of Ophthalmology
1999; 128: 15-20
5415
Audible pops during cyclodiode procedures
Altuna JC; Greenfield DS; Wand M; Liebmann JM; Taglia DP; Kaufmann PL; Cioffi GA; Lee DA; Robin AL; Crichton A
Journal of Glaucoma
1999; 8: 177-183
5416
A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension
Eisenberg DL; Camras CB
Drug Safety
1999; 20: 505-514
5417
Iris pigmentation in two cases following topical instillation of isopropyl unoprostone
Iwakuchi Y; Tanahashi T; Shirao Y
Japanese Journal of Clinical Ophthalmology
1999; 53: 971-974
5418
Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit (comment)
Kaufman HE; Varnell ED; Thompson HW
American Journal of Ophthalmology
1999; 127: 531-536
5419
Prostaglandin analogues in the treatment of glaucoma
Linden C; Alm A
Drugs and Aging
1999; 14: 387-398
5420
Clinical experience with latanoprost: a retrospective study of 153 patients
Martin L
Acta Ophthalmologica Scandinavica
1999; 77: 336-339
5421
In vivo effect of 8-epi-PGF2alpha on retinal circulation in diabetic and non-diabetic rats
Michoud E; Lecomte M; Lagarde M; Wiernsperger N
Prostaglandins Leukotrienes and Essential Fatty Acids
1998; 59: 349-355
5422
Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension.
Moroi SE; Gottfredsdottir MS; Schteingart MT; Elner SG; Lee CM; Schertzer RM; Abrams GW; Johnson MW
Ophthalmology
1999; 106: 1024-1029
5423
Comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF(2 alpha ) metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension
Nordmann J-P; Rouland J-F; Mertz BP
Current Medical Research and Opinion
1999; 15: 87-93
5424
Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway.
Sagara T; Gaton DD; Lindsey JD; Gabelt BT; Kaufman PL; Weinreb RN
Archives of Ophthalmology
1999; 117: 794-801
5425
Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories.
Sjoequist B; Johansson A; Stjernschantz J
Arzneimittel-Forschung/Drug Research
1999; 49: 240-249
5426
Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.
Sjoequist B; Tajallaei S; Stjernschantz J
Arzneimittel-Forschung/Drug Research
1999; 49: 225-233
5427
Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye.
Sjoequist B; Uhlin A; Byding P; Stjernschantz J
Arzneimittel-Forschung/Drug Research
1999; 49: 234-239
5428
Latanoprost and herpes simplex keratitis (see comments)
Wand M; Gilbert CM; Liesegang TJ
American Journal of Ophthalmology
1999; 127: 602-604
5429
Latanoprost in the treatment of glaucoma and ocular hypertension
Watson PG
Drugs of Today
1999; 35: 449-459
Issue
1-2
Table of Contents
Editor's Selection
Change Issue
24-2 (2024)
24-1 (2024)
23-4 (2023)
23-3 (2023)
23-2 (2023)
23-1 (2022)
22-4 (2022)
22-3 (2022)
22-2 (2021)
22-1 (2021)
21-4 (2021)
21-3 (2021)
21-2 (2021)
21-1 (2020)
20-4 (2020)
20-3 (2020)
20-2 (2019)
20-1 (2019)
19-4 (2019)
19-3 (2018)
19-2 (2018)
19-1 (2018)
18-4 (2017)
18-3 (2017)
18-2 (2017)
18-1 (2017)
17-4 (2016)
17-3 (2016)
17-2 (2016)
17-1 (2016)
16-4 (2015)
16-3 (2015)
16-2 (2015)
16-1 (2014)
15-4 (2014)
15-3 (2014)
15-2 (2013)
15-1 (2013)
14-4 (2013)
14-3 (2013)
14-2 (2013)
14-1 (2012)
13-4 (2012)
13-3 (2011)
13-2 (2011)
13-1 (2011)
12-4 (2011)
12-3 (2010)
12-2 (2010)
12-1 (2010)
11-4 (2010)
11-3 (2009)
11-2 (2009)
11-1 (2009)
10-4 (2009)
10-3 (2008)
10-2 (2008)
10-1 (2008)
9-4 (2008)
9-3 (2007)
9-2 (2007)
9-1 (2007)
8-4 (2007)
8-3 (2006)
8-2 (2006)
8-1 (2006)
7-3 (2006)
7-2 (2005)
7-1 (2005)
6-3 (2005)
6-2 (2004)
6-1 (2004)
5-3 (2004)
5-2 (2003)
5-1 (2003)
4-3 (2003)
4-2 (2002)
4-1 (2002)
3-3 (2002)
3-2 (2001)
3-1 (2001)
2-3 (2001)
2-2 (2000)
2-1 (2000)
1-3 (2000)
1-2 (1999)
1-1 (1999)
advertisement